Jiahong Dental 2026H1: Revenue of RMB 272 million, up 5.68% YoY, with overseas revenue accounting for nearly 60%.

Source: Jiahong Dental 2026 Interim Report

Revenue of RMB 272 million (up 5.68% year-on-year) / Implant product revenue of RMB 160 million / Overseas main business revenue up 15.02% year-on-year

DentalGoodNews｜August 26, 2026, Shenzhen Jiahong Dental Co., Ltd. (hereinafter referred to as "Jiahong Dental") released its 2026 semi-annual report. During the reporting period, the company achieved operating revenue of RMB 272 million, up 5.68% year-on-year; net profit attributable to shareholders of the listed company was RMB 26.7777 million, down 8.54% year-on-year. Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 26.3673 million, down 6.77% year-on-year. Overall, during the reporting period, the company's gross margin was 37.18%, an improvement from 34.05% in the same period of the previous year. Jiahong Dental stated that during the reporting period, the company's exchange losses amounted to RMB 6.5432 million (the absolute value of which accounted for 21.38% of the current period's total profit), and exchange rate fluctuations had a significant impact on performance.

Source: Jiahong Dental 2026 Interim Report

From a product line perspective, denture products achieved revenue of RMB 108 million during the reporting period, up 8.60% year-on-year, with operating costs up 3.87% year-on-year and gross margin up 2.79 percentage points year-on-year to 37.56%. Implant products achieved revenue of RMB 160 million, down 10.17% year-on-year, with operating costs down 14.64% year-on-year and gross margin up 4.05 percentage points year-on-year to 36.54%.

In terms of market structure, during the reporting period, Jiahong Dental's overseas main business revenue was RMB 160 million, up 15.02% year-on-year, with operating costs up 11.00% year-on-year and gross margin up 2.30 percentage points year-on-year to 36.54%, accounting for 59.60% of main business revenue; domestic main business revenue was RMB 108 million, down 4.66% year-on-year, with operating costs down 11.17% year-on-year and gross margin up 4.58 percentage points year-on-year to 37.56%. According to previous reports by DGN, in 2025, Jiahong Dental actively responded to tariff uncertainties and expanded overseas markets through measures such as establishing overseas subsidiaries.

Source: Jiahong Dental 2026 Interim Report

In terms of R&D investment, during the reporting period, the company's R&D expenses were RMB 12.841 million, up 3.94% year-on-year, accounting for 4.71% of operating revenue. On the expense side, selling expenses were RMB 28.0969 million, up 5.62% year-on-year; administrative expenses were RMB 16.402 million, up 6.58% year-on-year. Financial expenses were RMB 5.9674 million (RMB -3.7668 million in the same period of the previous year), a change of -258.42% year-on-year, mainly due to increased exchange losses caused by foreign exchange rate fluctuations. In addition, the company's asset impairment loss was RMB 2.4957 million (RMB 98,200 in the same period of the previous year), expanding significantly year-on-year, mainly due to the increase in inventory write-down provisions made in the current period.

Source: Jiahong Dental 2026 Interim Report

In terms of cash flow, in the first half of 2026, Jiahong Dental's net cash flow from operating activities was RMB 43.3188 million, up 212.92% from RMB 13.8436 million in the same period of the previous year; net cash flow from investing activities was RMB -4.8042 million, down 33.85% year-on-year; net cash flow from financing activities was RMB -20.6004 million, up 4.98% year-on-year.

In addition, Jiahong Dental is actively advancing its listing process. According to previous reports by DGN, the company passed the Beijing Stock Exchange listing guidance acceptance review by the Shenzhen Regulatory Bureau on July 2, 2026. The semi-annual report shows that as of June 30, 2026, the company's total assets reached RMB 675 million, up 2.13% year-on-year, with book value per share attributable to shareholders of the parent company at RMB 7.57.